Overview

Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory follicular (FL) or marginal one (MZL) lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Nanjing Sanhome Pharmaceutical, Co., Ltd.